Varenicline as a smoking cessation aid in schizophrenia: Effects on smoking behavior and reward sensitivity

Psychopharmacology

Volumn 219, Issue 1, 2012, Pages 25-34

  Dutra, Sunny J ^a   Stoeckel, Luke E ^b   Carlini, Sara V ^b   Pizzagalli, Diego A ^c   Evins, A Eden ^b  

^a YALE UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

Affective flattening; Anhedonia; Nicotine; Reward; Schizophrenia; Smoking cessation; Varenicline

Indexed keywords

VARENICLINE;

ADULT; AGED; ANHEDONIA; APATHY; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REWARD; SCHIZOPHRENIA; SELF REPORT; SMOKING CESSATION; SMOKING HABIT; TASK PERFORMANCE; TOBACCO DEPENDENCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; BENZAZEPINES; COGNITIVE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; QUINOXALINES; REWARD; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION;

EID: 84856676758     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2373-6     Document Type: Article

References (69)

1. F Alhatem JE Black 2009 Varenicline-induced mania in a bipolar patient Clin Neuropharm 32 117 118 10.1097/WNF.0b013e31816f75bc
2. Andreasen N (1983) Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City
3. I Anghelescu 2009 Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient J Neuropsyc Clin Neurosci 21 102 110 10.1176/appi.neuropsych.21.1.102
4. RS Barr MA Culhane JE Jubelt, et al. 2008 The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls Neuropsychopharmacology 33 480 490 17443126 10.1038/sj.npp.1301423 1:CAS:528:DC%2BD1cXmsFSluw%3D%3D
5. RS Barr DA Pizzagalli MA Culhane DC Goff AE Evins 2008 A single dose of nicotine enhances reward responsiveness in non-smokers: implications for development of dependence Biol Psychiatry 63 1061 1065 17976537 10.1016/j.biopsych.2007.09.015 1:CAS:528:DC%2BD1cXmtVagsrg%3D (Pubitemid 351636295)
6. KC Berridge ML Kringelbach 2008 Affective neuroscience of pleasure: reward in humans and animals Psychopharmacology 199 457 480 18311558 10.1007/s00213-008-1099-6 1:CAS:528:DC%2BD1cXotVyrtrw%3D
7. KC Berridge TE Robinson JW Aldridge 2009 Dissecting components of reward: 'liking', 'wanting', and learning Curr Opin Pharmacol 9 65 73 19162544 10.1016/j.coph.2008.12.014 1:CAS:528:DC%2BD1MXhsFKks7w%3D
8. J Bobes C Arango M Garcia-Garcia J Rejas 2010 Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort Schizophr Res 119 101 109 20219322 10.1016/j.schres.2010.02.1030
9. AL Brody RE Olmstead ED London, et al. 2004 Smoking-induced ventral striatum dopamine release Am J Psychiatry 161 1211 1218 15229053 10.1176/appi.ajp.161.7.1211 (Pubitemid 38859170)
10. ML Bruce PJ Leaf L Florio RA Hoff 1994 Psychiatric status and 9-year mortality data in the New Haven epidemiological catchment area study Am J Psychiatry 151 716 721 8166313 1:STN:280:DyaK2c3hvFKmug%3D%3D (Pubitemid 24140561)
11. BS Bunney LA Chiodo AA Grace 1991 Midbrain dopamine system electrophysiological functioning: a review and new hypothesis Synapse 9 79 94 1821487 10.1002/syn.890090202 1:CAS:528:DyaK38XnsVA%3D
12. Cahill K, Stead LF, Lancaster T (2008) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 3:CD006103
13. 2 stimulation and blockade on smoking behavior Exp Clin Psychopharm 7 72 78 10.1037/1064-1297.7.1.72 1:CAS:528:DyaK1MXitFeqtrk%3D (Pubitemid 29085091)
14. B Cinemre ST Akdag O Metin O Doganavsargil 2010 Varenicline-induced psychosis CNS Spectr 15 469 472
15. 2/3 receptor binding in rats Addict Biol 14 500 502 19650815 10.1111/j.1369-1600.2009.00168.x 1:CAS:528: DC%2BD1MXht1yntr3I
16. 3 receptor expression in blood lymphocytes of smokers is negatively correlated with daily number of smoked cigarettes: a peripheral correlate of dopaminergic alterations in smokers Nicotine Tob Res 6 49 54 14982687 10.1080/ 14622200310001656858 1:CAS:528:DC%2BD2cXhsFajsrc%3D (Pubitemid 38372473)
17. A Dagher C Bleicher JAD Aston RN Gunn PBS Clarke P Cumming 2001 Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers Synapse 42 48 53 11668590 10.1002/syn.1098 1:CAS:528:DC%2BD3MXmtlCqs7o%3D (Pubitemid 32786423)
18. GW Dalack DJ Healy JH Meador-Woodruff 1998 Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings Am J Psychiatry 155 1490 1501 9812108 1:STN:280:DyaK1M%2FivVKnsA%3D%3D (Pubitemid 28512015)
19. KL Davis RS Kahn M Davidson 1991 Dopamine in schizophrenia: a review and reconceptualization Am J Psychiatry 148 1474 1486 1681750 1:STN:280: DyaK38%2Fis1GksQ%3D%3D
20. BJ Everitt TW Robbins 2005 Neural systems of reinforcement for drug addiction: from actions to habits to compulsion Nat Neurosci 8 1481 1489 16251991 10.1038/nn1579 1:CAS:528:DC%2BD2MXhtFCrurbI (Pubitemid 41573659)
21. AE Evins DC Goff 2008 Varenicline treatment for smokers with schizophrenia: a case series J Clin Psychiatry 69 1016 18683999 10.4088/JCP.v69n0620a (Pubitemid 351944959)
22. K Fagerstrom 2002 The epidemiology of smoking: health consequences and benefits of cessation Drugs 62 1 9 12109931 10.2165/00003495-200262002-00001 (Pubitemid 34809710)
23. K Fagerstrom DJ Balfour 2006 Neuropharmacology and potential efficacy of new treatments for tobacco dependence Expert Opin Investig Drugs 15 107 116 16433591 10.1517/13543784.15.2.107 (Pubitemid 43250754)
24. SH Fatemi 2008 Varenicline efficacy and tolerability in a subject with schizophrenia Schizophr Res 103 328 329 18572388 10.1016/j.schres.2008.05.002
25. 2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse Am J Psychiatry 16 507 514 10.1176/appi.ajp.2007.07020352 (Pubitemid 351694294)
26. J Foulds 2006 The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline Int J Clin Pract 60 571 576 16700857 10.1111/j.1368-5031.2006.00955.x 1:CAS:528:DC%2BD28XltlGntrk%3D
27. R Freedman 2007 Exacerbation of schizophrenia by varenicline Am J Psychiatry 164 1269 17671295 10.1176/appi.ajp.2007.07020326 (Pubitemid 47292423)
28. K Fukui T Kobayashi S Hayakawa, et al. 1995 Smoking habits in chronic schizophrenics Arukoru Kenkyuto Yakabutsu Izon 30 447 454 1:STN:280: DyaK287msF2qsQ%3D%3D (Pubitemid 26034415)
29. LJ Gholson 2008 Possible varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline personality disorder, and methamphetamine abuse in remission J Clin Psychopharmacol 28 720 721 10.1097/JCP.0b013e31818db354
30. N Ginovart L Farde C Halldin CG Swahn 1999 Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates Synapse 31 154 162 10024013 10.1002/(SICI)1098- 2396(199902)31:2<154::AID-SYN9>3.0.CO;2-K 1:CAS:528:DyaK1MXmt1Wl (Pubitemid 29187364)
31. AH Glassman 1993 Cigarette smoking: implications for psychiatric illness Am J Psychiatry 150 546 553 8465868 1:STN:280:DyaK3s3itVOgsg%3D%3D (Pubitemid 23109920)
32. DC Goff DC Henderson E Amico 1992 Cigarette smoking in schizophrenia: relationships to psychopathology and medication side effects Am J Psychiatry 149 1189 1194 1503131 1:STN:280:DyaK38zmslOqsg%3D%3D
33. AA Grace 1991 Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia Neuroscience 41 1 24 1676137 10.1016/0306-4522(91)90196-U 1:CAS:528: DyaK3MXisVGiur8%3D
34. RG Hall M Duhamel R McClanahan, et al. 1995 Level of functioning, severity of illness, and smoking status among chronic psychiatric patients J Nerv Ment Dis 183 468 471 7623020 10.1097/00005053-199507000-00008 1:STN:280:DyaK2MzkvVKrtg%3D%3D
35. Hautus MJ (1995) Corrections for extreme proportions and their biasing effects on estimated values of d'. Beh Res Methods Instrum Comput 27:46-51
36. TF Heatherton LT Kozlowski RC Frecker KO Fagerstrom 1991 The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire Br J Addict 86 1119 1127 1932883 10.1111/j.1360-0443.1991.tb01879. x 1:STN:280:DyaK38%2Fjtlejtg%3D%3D
37. EA Heerey KR Bell-Warren JM Gold 2008 Decision-making impairments in the context of intact reward sensitivity in schizophrenia Biol Psychiatry 64 62 69 18377874 10.1016/j.biopsych.2008.02.015
38. A Heinz MB Knable R Coppola, et al. 1998 Psychomotor slowing, negative symptoms and dopamine receptor availability-an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients Schizophr Res 31 19 26 9633833 10.1016/S0920-9964(98)00003-6 1:STN:280:DyaK1c3psFGqsg%3D%3D (Pubitemid 28234341)
39. JM Irving EC Clark IK Crombie WC Smith 1988 Evaluation of a portable measure of expired-air carbon monoxide Prev Med 17 109 115 3362796 10.1016/0091-7435(88)90076-X 1:STN:280:DyaL1c3gtlCqtg%3D%3D
40. EM Joyce SL Collinson P Crichton 1996 Verbal fluency in schizophrenia: relationship with executive function, semantic memory and clinical alogia Psychol Med 26 39 49 8643762 10.1017/S0033291700033705 1:STN:280: DyaK283gs1Oitw%3D%3D (Pubitemid 26031802)
41. L Jubelt R Barr D Goff T Logvinenko A Weiss A Evins 2008 Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia Psychopharmacology 199 89 98 18548234 10.1007/s00213-008-1133-8 1:CAS:528:DC%2BD1cXnvVKhu7Y%3D
42. G Juckel F Schlagenhauf M Koslowski, et al. 2006 Dysfunction of ventral striatal reward prediction in schizophrenia Neuroimage 29 409 416 16139525 10.1016/j.neuroimage.2005.07.051 (Pubitemid 43063297)
43. JS Kim HH Komhuber W Schmid-Burgk B Holzmiller 1980 Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia Neurosci Lett 20 379 382 6108541 10.1016/0304-3940(80)90178-0 1:CAS:528:DyaL3MXhtlOksA%3D%3D (Pubitemid 11160082)
44. BJ Kinon JA Lieberman 1996 Mechanisms of action of atypical antipsychotic drugs: a critical analysis Psychopharmacology (Berl) 124 2 34 10.1007/BF02245602 1:CAS:528:DyaK28XjsFGktL0%3D (Pubitemid 26111436)
45. JL Martinot ML Palliere-Martinot C Loc'h, et al. 1994 Central D2 receptors and negative symptoms of schizophrenia Br J Psychiatry 164 27 34 8137107 10.1192/bjp.164.1.27 1:STN:280:DyaK2c7osVOqsw%3D%3D
46. PR Montague P Dayan TJ Sejnowski 1996 A framework for mesencephalic dopamine systems based on predictive Hebbian learning J Neurosci 16 1936 1947 8774460 1:CAS:528:DyaK28Xht1GlsLc%3D (Pubitemid 26145969)
47. RJ Moore SL Vinsant MA Nader LJ Porrino DP Friedman 1998 Effect of cocaine self-administration on striatal dopamine D1 receptors in rhesus monkeys Synapse 28 1 9 9414012 10.1002/(SICI)1098-2396(199801)28:1<1::AID-SYN1>3. 0.CO;2-G 1:CAS:528:DyaK2sXns1Kmsrw%3D (Pubitemid 128770597)
48. M Nisell GG Nomikos TH Svensson 1995 Nicotine dependence, midbrain dopamine systems and psychiatric disorders Basic Clin Pharmacol Toxicol 76 157 162 1:CAS:528:DyaK2MXkslWnsLY%3D
49. AA Patkar R Gopalakrishnan A Lundy FT Leone SP Weinstein 2002 Relationship between tobacco smoking and positive and negative symptoms in schizophrenia J Nerv Ment Dis 190 604 610 12357094 10.1097/00005053-200209000- 00005
50. DA Pizzagalli AL Jahn JP O'Shea 2005 Toward an objective characterization of an anhedonic phenotype: a signal detection approach Biol Psychiatry 57 319 327 15705346 10.1016/j.biopsych.2004.11.026 (Pubitemid 40215760)
51. DA Pizzagalli AE Evins EC Schetter, et al. 2008 Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness Psychopharmacology (Berl) 196 221 232 10.1007/s00213-007-0957-y 1:CAS:528:DC%2BD1cXpsF2ksA%3D%3D
52. DA Pizzagalli D Iosifescu LA Hallett KG Ratner M Fava 2009 Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task J Psychiatr Res 43 76 87 10.1016/j.jpsychires.2008.03.001
53. MK Popkin 2008 Exacerbation of recurrent depression as a result of treatment with varenicline Am J Psychiatry 165 774 18519539 10.1176/appi.ajp. 2008.07111735 (Pubitemid 351810551)
54. KJ Preacher AF Hayes 2004 SPSS and SAS procedures for estimating indirect effects in simple mediation models Behav Res Meth Ins C 36 717 731 10.3758/BF03206553 (Pubitemid 40251423)
55. TE Robinson KC Berridge 1993 The neural basis of drug craving: an incentive-sensitization theory of addiction Brain Res Rev 18 247 291 8401595 10.1016/0165-0173(93)90013-P 1:CAS:528:DyaK3sXlsFWnu78%3D (Pubitemid 23219500)
56. RM Roth LA Flashman AJ Saykin TW McAllister R Vidaver 2004 Apathy in schizophrenia: reduced frontal lobe volume and neuropsychological deficits Am J Psychiatry 161 157 159 14702265 10.1176/appi.ajp.161.1.157 (Pubitemid 38419322)
57. K Schmidt B Nolte-Zenker J Patzer M Bauer LG Schmidt A Heinz 2001 Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence Pharmacopsychiatry 34 66 72 11302566 10.1055/s-2001-15184 1:CAS:528:DC%2BD3MXisVequ7Y%3D (Pubitemid 32221751)
58. W Schultz 2002 Getting formal with dopamine and reward Neuron 36 241 263 12383780 10.1016/S0896-6273(02)00967-4 1:CAS:528:DC%2BD38XotlansLo%3D (Pubitemid 35217890)
59. DJ Scott EF Domino MM Heitzeg, et al. 2007 Smoking modulation of μ-opioid and dopamine D2 receptor-mediated neurotransmission in humans Neuropsychopharmacol 32 450 457 10.1038/sj.npp.1301238 1:CAS:528: DC%2BD2sXltlSisw%3D%3D (Pubitemid 46106951)
60. 2 receptor in schizophrenia Expert Opin Ther Targets 10 515 531 16848689 10.1517/14728222.10. 4.515 1:CAS:528:DC%2BD28Xnt1ahtro%3D (Pubitemid 44165124)
61. H Silver P Feldman 2005 Evidence for sustained attention and working memory in schizophrenia sharing a common mechanism J Neuropsychiatry Clin Neurosci 17 391 398 16179663 10.1176/appi.neuropsych.17.3.391 (Pubitemid 46194095)
62. S Silvestri JC Negrete MG Seeman CM Shammi P Seeman 2004 Does nicotine affect D2 receptor upregulation? A case control study Acta Psychiatr Scand 109 313 317 15008806 10.1111/j.1600-0447.2004.00293.x 1:STN:280: DC%2BD2c7mslSmsA%3D%3D (Pubitemid 38406714)
63. RC Smith A Singh M Infante A Khandat A Kloos 2002 Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia Neuropsychopharmacology 27 479 497 12225705 10.1016/S0893-133X(02) 00324-X 1:CAS:528:DC%2BD38XmvVWqsLk%3D (Pubitemid 35253795)
64. RC Smith JP Lindenmayer JM Davis, et al. 2009 Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder Schizophr Res 110 149 155 19251401 10.1016/j.schres.2009.02.001
65. G Tripp B Alsop 1999 Sensitivity to reward frequency in boys with attention deficit hyperactivity disorder J Clin Child Psychol 28 366 375 10446686 10.1207/S15374424jccp280309 1:STN:280:DyaK1MznsFyqsA%3D%3D
66. 2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzepine and clozapine Psychiatry Clin Neurosci 63 529 537 10.1111/j.1440-1819.2009.01982.x
67. 2 receptor levels Am J Psychiatry 156 1440 1443 10484959 1:STN:280:DyaK1MvhsVKitw%3D%3D (Pubitemid 29416545)
68. Wechsler D (2001) Wechsler Test of Adult Reading (WTAR). The Psychological Corporation, San Antonio
69. G Winterer 2010 Why do patients with schizophrenia smoke? Curr Opin Psychiatr 23 112 119 10.1097/YCO.0b013e3283366643